United States

People: Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

16 Aug 2019
Change (% chg)

$0.31 (+4.45%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Townsend, Raymond 

Dr. Raymond Townsend is an Independent Director of Kindred Biosciences Inc. He was appointed to our Board of Directors on November 11, 2013. From 2001 until his retirement in 2017, Dr. Townsend served as the President of Wasatch Health Outcomes, Inc., his personal consulting firm engaged in providing support for pharmaceutical product development, pricing and commercialization. From 1978 to 1988, Dr. Townsend was employed in various positions at the Upjohn Company, where he pioneered the first modern pharmacoeconomic research department within the pharmaceutical industry. Between 1988 and 1997, he served in various positions at Glaxo (now GlaxoSmithKline), culminating in the positions of Worldwide Director and Vice President, Outcomes, Epidemiology and Policy Research. Between 1998 and 2001, he was co-founder and Chief Executive Officer of Strategic Outcomes Services, Inc. From 2004 to 2009, he was Senior Vice President, Pharmacoeconomic & Epidemiology Outcomes Research, at Elan Pharmaceuticals, Inc. Dr. Townsend earned a B.A. in Economics at California State University and his Doctor of Pharmacy degree from the University of California, San Francisco. Dr. Townsend is well qualified to serve as a director because of his extensive experience in senior management roles in the pharmaceutical industry.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 354,866
Fiscal Year Total, USD 354,866

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Denise Bevers


Richard Chin


Wendy Wee


Hangjun Zhan


Ernest Mario


Joseph McCracken

As Of  30 Dec 2018